Article
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
The Lancet. Oncology - 1 Aug 2010
De Roock Wendy, Claes Bart, Bernasconi David, De Schutter Jef, Biesmans Bart, Fountzilas George, Kalogeras Konstantine T, Kotoula Vassiliki, Papamichael Demetris, Laurent-Puig Pierre, Penault-Llorca Frédérique, Rougier Philippe, Vincenzi Bruno, Santini Daniele, Tonini Giuseppe, Cappuzzo Federico, Frattini Milo, Molinari Francesca, Saletti Piercarlo, De Dosso Sara, Martini Miriam, Bardelli Alberto, Siena Salvatore, Sartore-Bianchi Andrea, Tabernero Josep, Macarulla Teresa, Di Fiore Frédéric, Gangloff Alice Oden, Ciardiello Fortunato, Pfeiffer Per, Qvortrup Camilla, Hansen Tine Plato, Van Cutsem Eric, Piessevaux Hubert, Lambrechts Diether, Delorenzi Mauro, Tejpar Sabine
Abstract excerpt
BACKGROUND: Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer are now profiled for seven KRAS mutations before receiving cetuximab or panitumumab. However, most patients with KRAS wild-type tumours still do not respond. We studied the effect of other downstream mutations on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.